Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Compiles New Clinical Assessment Guidelines on Neuropathic Pain Drugs
January 7, 2021
- MHLW Informs of New Guideline on Exemption from Bioequivalence Studies for Oral Drugs
January 7, 2021
- Govt Eager to Roll Out 1st COVID-19 Vaccine by Late February; PM Says Pfizer’s Japan Data Ready by Month-End
January 5, 2021
- AMED to Fund 14 Projects under CiCLE Program
January 5, 2021
- 3 API Manufacturing Repatriation Projects by Meiji, Nipro, Shionogi Adopted for MHLW Funding
January 5, 2021
- MHLW Approves Label Expansions for Olumiant, Gardasil, Lynparza and More
December 28, 2020
- MHLW Grants Orphan Status to 5 APIs
December 28, 2020
- Japan’s Drug Production Swells 37.3% to 9.5 Trillion Yen in 2019: MHLW Survey
December 28, 2020
- MHLW Drafts Guidelines for Use of Patient Registry Data in Regulatory Filing
December 25, 2020
- Japan Prepping to Expand Veklury Label beyond Severe COVID-19: PMDA
December 25, 2020
- Coronavirus Panel Draws Up Plan for Vaccination System, Priority
December 25, 2020
- Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
December 24, 2020
- MHLW to Disclose Members’ Names, Minutes of Drug Pricing, Cost-Effectiveness Analysis Organizations to Enhance Transparency
December 24, 2020
- Govt’s Reform Panel to Draw Up Framework by Next Summer for Permanent Telemedicine Rollout, with Reimbursement Policies
December 24, 2020
- MHLW’s FY2021 Budget Record 33 Trillion-Plus Yen
December 23, 2020
- MHLW Orders Label Revision for Xylocaine; Advising Careful Administration in Ears and Digits
December 23, 2020
- MHLW’s Health Policy Bureau Allocated 129 Million Yen for Setting Up R&D Promotion Network
December 23, 2020
- 700 Million Yen Allocated for COVID-19 Control Measures in FY2021: MHLW’s Pharm Safety Bureau
December 23, 2020
- 0.8% Add-On to Adjustment Rate Set to Soften Impact on Drug Distribution: MHLW
December 22, 2020
- MHLW Official Says Biz Suspension on Kobayashi Kako Inevitable
December 22, 2020
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…